Latest news with #BiotechnologyforEconomy
United News of India
2 days ago
- Health
- United News of India
Experts meet to boost monoclonal antibody innovation in India
New Delhi, June 10 (UNI) Leading voices from the pharmaceutical industry, biotech start-ups, funding agencies such as BIRAC, and premier academic institutions convened on Tuesday to explore new strategies for accelerating monoclonal antibody (mAb) therapies in India. Such a therapy uses antibodies, made in a lab, to target and treat specific diseases, including cancer. The symposium, organised by the Translational Health Science and Technology Institute (THSTI), highlighted India's rapidly growing biopharmaceutical sector and noted the vast potential for indigenous innovation in the development of mAb therapies—critical tools in precision medicine. A recurring theme throughout the discussions was the need for early and sustained collaboration between academia and industry, particularly at the innovation and discovery stages. Such partnerships, experts agreed, are vital to developing affordable, homegrown technologies that serve national healthcare needs, said a statement from the Union Science and Technology. Prof. Jayanta Bhattacharya, Dean of THSTI, stressed that bridging the gap between scientific research and industrial application is essential to ensure India's self-reliance in biologics. Echoing this, Prof. G. Karthikeyan, Executive Director of THSTI, highlighted the importance of establishing innovation clusters where industry and academia can collaborate closely. These clusters, he said, would also serve as talent hubs, fostering the next generation of skilled professionals. Dr. Alka Sharma, Senior Adviser at the Department of Biotechnology (DBT), outlined the government's Bio-E3 policy (Biotechnology for Economy, Environment & Employment). She reaffirmed DBT's commitment to advancing mAb platforms, which are vital for addressing complex diseases and ensuring equitable access to high-quality biologics. She emphasised that the Bio-E3 initiative aims to build biotech self-reliance, reduce dependency on imports, and strengthen domestic R&D capacity through targeted investments in technologies like mAbs. The symposium served as a dynamic platform for cross-sector dialogue, reinforcing the belief that strategic collaboration and policy support are key to unlocking India's full potential in the global biopharmaceutical landscape, added the statement. UNI AJ SSP
Business Wire
2 days ago
- Science
- Business Wire
Redwire Selected by NASA to Facilitate Biotechnology Research as Part of Historic International Human Spaceflight Mission
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next- generation space economy, announced today that it has been selected by NASA to facilitate a Space Microalgae biotechnology experiment. The experiment, developed by the Indian Space Research Organization (ISRO), the International Centre for Genetic Engineering and Biotechnology (ICGEB), and the National Institute of Plant Genome Research (NIPGR), New Delhi will launch on Axiom Mission 4 (Ax-4) to the International Space Station (ISS). The Space Microalgae investigation will analyze the impact of microgravity on the growth, metabolism, and genetic activity of three strains of edible microalgae, which researchers are assessing as a potential sustainable food source for long-duration space missions. For this research mission, Redwire will manage mission integration, scientific fulfillment, and on orbit operations. 'Redwire is proud to be working with NASA, ISRO, the ICGEB, and NIPGR on this multinational biotechnology research effort that could have significant implications for future long-duration spaceflight missions to the Moon and Mars,' said John Vellinger, Redwire's President of In-Space Industries. 'As a global leader in microgravity research and development technologies, it is incredibly exciting to contribute to global scientific progress in sustainable food sources for long-duration space missions. 'We are excited to engage with Redwire to launch this important investigation to the ISS,' said Dr. Shashi Kumar from the ICGEB. 'This work will help advance our knowledge of microalgae as supplement for crew nutrition so critical for the future of long-duration spaceflight. The Government of India's BioE3 (Biotechnology for Economy, Environment, and Employment) policy has an important vertical on space biomanufacturing, and this work is the first space project to be supported under it.' Redwire is the global leader in microgravity research, development, and manufacturing technologies, specializing in space biotechnology, pharmaceutical development, and plant research. Redwire has more than three decades of human spaceflight heritage and experience producing and operating systems and currently owns nine payloads and facilities aboard the ISS, including Redwire's trailblazing BioFabrication Facility and PIL-BOX platform. Leveraging these unique capabilities, Redwire has successfully bio-printed the first-ever human knee meniscus and first live human heart tissue in space and has successfully grown small molecule crystals optimized for drug development in microgravity. Ax-4 will launch an international crew of astronauts from India, Poland, Hungary, and the United States to the ISS marking the second human spaceflight mission for India, Poland, and Hungary. It will also be the first time all three nations will conduct an investigation on board the ISS. About Redwire Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire's proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire's approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit
Yahoo
2 days ago
- Science
- Yahoo
Redwire Selected by NASA to Facilitate Biotechnology Research as Part of Historic International Human Spaceflight Mission
JACKSONVILLE, Fla., June 10, 2025--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next- generation space economy, announced today that it has been selected by NASA to facilitate a Space Microalgae biotechnology experiment. The experiment, developed by the Indian Space Research Organization (ISRO), the International Centre for Genetic Engineering and Biotechnology (ICGEB), and the National Institute of Plant Genome Research (NIPGR), New Delhi will launch on Axiom Mission 4 (Ax-4) to the International Space Station (ISS). The Space Microalgae investigation will analyze the impact of microgravity on the growth, metabolism, and genetic activity of three strains of edible microalgae, which researchers are assessing as a potential sustainable food source for long-duration space missions. For this research mission, Redwire will manage mission integration, scientific fulfillment, and on orbit operations. "Redwire is proud to be working with NASA, ISRO, the ICGEB, and NIPGR on this multinational biotechnology research effort that could have significant implications for future long-duration spaceflight missions to the Moon and Mars," said John Vellinger, Redwire's President of In-Space Industries. "As a global leader in microgravity research and development technologies, it is incredibly exciting to contribute to global scientific progress in sustainable food sources for long-duration space missions. "We are excited to engage with Redwire to launch this important investigation to the ISS," said Dr. Shashi Kumar from the ICGEB. "This work will help advance our knowledge of microalgae as supplement for crew nutrition so critical for the future of long-duration spaceflight. The Government of India's BioE3 (Biotechnology for Economy, Environment, and Employment) policy has an important vertical on space biomanufacturing, and this work is the first space project to be supported under it." Redwire is the global leader in microgravity research, development, and manufacturing technologies, specializing in space biotechnology, pharmaceutical development, and plant research. Redwire has more than three decades of human spaceflight heritage and experience producing and operating systems and currently owns nine payloads and facilities aboard the ISS, including Redwire's trailblazing BioFabrication Facility and PIL-BOX platform. Leveraging these unique capabilities, Redwire has successfully bio-printed the first-ever human knee meniscus and first live human heart tissue in space and has successfully grown small molecule crystals optimized for drug development in microgravity. Ax-4 will launch an international crew of astronauts from India, Poland, Hungary, and the United States to the ISS marking the second human spaceflight mission for India, Poland, and Hungary. It will also be the first time all three nations will conduct an investigation on board the ISS. About Redwire Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire's proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire's approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit View source version on Contacts Media Contact: Emily 305-632-9137 Investors: investorrelations@ 904-425-1431 Sign in to access your portfolio
